Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia.

Jasmijn D E de Rooij, Eva Beuling, Marry M van den Heuvel-Eibrink, Askar Obulkasim, André Baruchel, Jan Trka, Dirk Reinhardt, Edwin Sonneveld, Brenda E S Gibson, Rob Pieters, Martin Zimmermann, C Michel Zwaan, Maarten Fornerod

Journal: Haematologica 2016;100(9):1151-9

PMID: 26069293

Abstract

IKAROS family zinc finger 1/IKZF1 is a transcription factor important in lymphoid differentiation, and a known tumor suppressor in acute lymphoid leukemia. Recent studies suggest that IKZF1 is also involved in myeloid differentiation. To investigate whether IKZF1 deletions also play a role in pediatric acute myeloid leukemia, we screened a panel of pediatric acute myeloid leukemia samples for deletions of the IKZF1 locus using multiplex ligation-dependent probe amplification and for mutations using direct sequencing. Three patients were identified with a single amino acid variant without change of IKZF1 length. No frame-shift mutations were found. Out of 11 patients with an IKZF1 deletion, 8 samples revealed a complete loss of chromosome 7, and 3 cases a focal deletion of 0.1-0.9Mb. These deletions included the complete IKZF1 gene (n=2) or exons 1-4 (n=1), all leading to a loss of IKZF1 function. Interestingly, differentially expressed genes in monosomy 7 cases (n=8) when compared to non-deleted samples (n=247) significantly correlated with gene expression changes in focal IKZF1-deleted cases (n=3). Genes with increased expression included genes involved in myeloid cell self-renewal and cell cycle, and a significant portion of GATA target genes and GATA factors. Together, these results suggest that loss of IKZF1 is recurrent in pediatric acute myeloid leukemia and might be a determinant of oncogenesis in acute myeloid leukemia with monosomy 7.

Copyright© Ferrata Storti Foundation.

Address: Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, the Netherlands.; Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, the Netherlands Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Hematology, Hopital Saint-Louis, Paris, France.; Pediatric Hematology/Oncology, 2nd Medical School, Charles University, Prague, Czech Republic.; AML-BFM Study Group, Pediatric Hematology/Oncology, Medical School Hannover, Germany.; Dutch Childhood Oncology Group (DCOG), The Hague, the Netherlands.; Royal Hospital for Sick Children, Glasgow, UK.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, the Netherlands [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.